Current Report Filing (8-k)
January 14 2022 - 5:13PM
Edgar (US Regulatory)
0001638287
false
0001638287
2022-01-14
2022-01-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 14, 2022
NeuroBo Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
|
|
001-37809
|
|
47-2389984
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
200 Berkeley Street, Office 19th Floor
Boston, Massachusetts 02116
(Address of principal executive offices, including Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (857) 702-9600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001 per share
|
|
NRBO
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company x
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 14, 2022, Mr. Douglas J.
Swirsky provided notice of his resignation from the Board of Directors (the “Board”) of NeuroBo Pharmaceuticals, Inc.
(the “Company”), effective immediately. Mr. Swirsky’s resignation was not the result of any disagreement
with the Company regarding the Company’s operations, policies or practices.
Andrew I. Koven, a current director of the Company
was elected Chairman of the Board and Michael Salsbury, a current director of the Company was appointed to the Audit Committee of the
Board and appointed Chairman of the Audit Committee. As a result, the Audit Committee of the Board currently consists of Jason Groves,
Andrew I. Koven, Michael Salsbury.
The Board has determined that each of Mr. Groves,
Mr. Koven and Mr. Salsbury are independent in accordance with the listing standards of Nasdaq and the Company’s internal
policies, and that each otherwise meets all applicable requirements to serve on the Audit Committee, including the rules and regulations
of the Securities and Exchange Commission (the “SEC”).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NEUROBO PHARMACEUTICALS, INC.
|
|
|
|
|
Date: January 14, 2022
|
By:
|
/s/ Gil Price
|
|
|
Gil Price
|
|
|
President and Chief Executive Officer
|
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Jul 2023 to Jul 2024